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Complete envelope genes were amplified from autopsy brain tissue of five individuals who had died of AIDS
and had neurological complications. Lymph node samples were included for two of the patients. Nineteen dif-
ferent envelope clones from the five patients had distinct V1V2 sequences. Thirteen of the envelopes were
functional and conferred fusigenicity and infectivity for CD4 CCR5 cells. Infectivity and cell-cell fusion
assays showed that most envelopes used both CCR5 and CCR3. One brain-derived envelope used a broad range
of coreceptors, while three other brain envelopes from one individual were restricted to CCR5. However, there
was no correlation between tissue of origin and coreceptor use. Envelopes showed two very distinct phenotypes
depending on their capacity to infect macrophages and to exploit low levels of CD4 and/or CCR5 for infection.
Envelopes that were highly fusigenic and tropic for macrophages were identified in brain tissue from four of
the five patients. The enhanced macrophage tropism correlated with reduced sensitivity to inhibition by Q4120,
a CD4-specific antibody, but not with sensitivity to the CCR5 inhibitor, TAK779. The highly macrophage-tropic
envelopes were able to infect cells expressing low levels of CD4 and/or CCR5. Comparison with several well-
characterized macrophage-tropic envelopes showed that the four identified patient envelopes were at the top
limit of macrophage tropism. In contrast, all four lymph node-derived envelopes exhibited a non-macrophage-
tropic phenotype and required high levels of CD4 for infection. Our data support the presence of envelopes that
are highly fusigenic and tropic for macrophages in the brains of patients with neurological complications.
These envelopes are able to infect cells that express low levels of CD4 and/or CCR5 and may have adapted for
replication in brain macrophages and microglia, which are known to express limited amounts of CD4.
Human immunodeficiency virus type 1 (HIV-1) replication
in the brain results in the development of severe neurological
disorders known as AIDS dementia complex in about 30% of
AIDS patients (29). The mechanisms that cause the loss of up
to 40% of neurons (10) as well as result in dementia are
unclear. In the rhesus macaque simian immunodeficiency virus
(SIV) model, both neurotropic and neurovirulent SIVMAC
variants have been described (11, 22, 38). It is therefore sus-
pected that specific neurotropic and neurovirulent HIV-1 vari-
ants exist and are associated with dementia.
CCR5-using HIV-1 strains are predominant in the brain
(13), and CCR5 perivascular macrophages and microglia are
the cell types most frequently infected (19, 35, 37, 43, 49, 50).
The role of other cell types resident in the brain is less clear.
There is evidence that CD4 astrocytes become infected, par-
ticularly in pediatric AIDS cases (32, 36, 37, 43). Astrocyte
infection is relatively unproductive with early HIV mRNAs
(e.g., for rev and nef) detectable, but no late mRNAs encoding
the structural gag and env proteins needed to produce progeny
virus particles (36, 37). Nevertheless, abundant expression of
nef and rev in brain astrocytes has been associated with demen-
tia (32). Infection of microvascular endothelial cells of the
blood brain barrier could represent a direct route for HIV
entry into the brain. However, few studies support more than
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sporadic infection (27, 46). Neurons have not been considered
a significant target for virus replication in vivo, although occa-
sional infection has been reported (25, 43). Two recent studies
using laser capture microscopy detected HIV-1 sequences in
isolated neurons (44, 45). These reports are intriguing and
could indicate latent infection but are currently difficult to
reconcile with the consensus from earlier studies indicating
only rare infection.
If neurotropic HIV-1 strains do exist, then they would be
expected to infect macrophages and microglia efficiently. Sev-
eral observations are consistent with this view. Shieh et al. de-
scribed a variant of the HIV-1 R5 strain, BORI, that replicated
more efficiently in microglial cultures following selection in
vitro (39). This increased microglial tropism was conferred by
mutations in the V1 loop, an envelope region that influences
cell tropism and coreceptor use (5, 34). Gorry et al. (16) re-
ported a brain isolate (UK1-br) that carried an enhanced fusi-
genicity and tropism for macrophages. Both Gorry’s brain iso-
late and Shieh’s microglia-passaged BORI variant had
increased capacity to infect cells expressing low levels of CD4
and CCR5 (16, 23, 39).
Analysis of the phenotypes of envelopes derived from brain
tissue has been limited mainly to viruses isolated into blood-
derived lymphocytes (15, 16, 42, 51) or envelope fragments
cloned into chimeric viruses (3). A recent report by Ohagen et
al. (28) described envelope genes that were amplified by PCR
from brain tissue without culture. Here, we describe genotypic
and biological characterization of full-length envelope genes
also amplified from brain tissue of AIDS patients taken at au-
topsy. PCR-amplified envelopes have not been through isola-
tion procedures that potentially select for virus strains able to
replicate fastest in donor peripheral blood mononuclear cell
(PBMC) cultures and may leave behind viruses adapted for rep-
lication in cell types resident in the brain. We describe several
brain-derived envelopes that have enhanced fusigenicity and
tropism for macrophages as well as the capacity to infect cells
that express low levels of CD4 and/or CCR5. We believe that
these envelopes have adapted for replication in macrophages
and microglia in the brain that express low levels of CD4.
MATERIALS AND METHODS
Patient tissue samples. Tissue samples dissected at autopsy were frozen at
80°C. Genomic DNA was extracted as described previously (40). Samples from
frontal lobe tissue of five late-term AIDS patients (NA118, NA420, NA20,
NA176, and NA353) and from the lymph node (LN) tissue of two of these
patients (NA118 and NA420) were used in this study. Information regarding
each patient is shown in Table 1.
PCR amplification of complete envelope genes. The gp160 PCRs were per-
formed using the Expand high fidelity DNA polymerase system (Roche Inc.)
according to the manufacturer’s instructions. This kit contains a mixture of a
polymerase with proofreading capability and Taq polymerase. NA118, NA420,
NA20, NA176, and NA353 envelope sequences were amplified by nested PCR as
described by Gao et al. (14). Outer primers were Env A (GGC TTA GGC ATC
TCC TAT GGC AGG AAG AA) and Env N (CTG CCA ATC AGG GAA GTA
GCC TTG TGT), and inner primers were Env B (AGA AAG AGC AGA AGA
CAG TGG CAA TGA) and Env M (TAG CCC TTC CAG TCC CCC CTT TTC
TTT TA). Conditions for both rounds of PCR were as follows: 94°C for 45 s,
50°C for 45 s, and 72°C for 4 min (20 cycles); 94°C for 45 s, 50°C for 45 s, and
72°C for 4 min 15 s (15 cycles). Between 0.01 and 1 g of patient DNA per
reaction was included. The PCR products were fractionated by agarose gel
electrophoresis, and 3-kb bands were excised and recovered using a gel extrac-
tion kit (QIAGEN Inc.). PCRs were carried out using a 5 chemically phosphor-
ylated PCR primer (Env B) in the second round of the nested PCR. The 3-kb
fragments thus contained a phosphate at the 5 end. These were then ligated into
the pCR3.1-Uni vector (Invitrogen Inc.) (see Fig. S1A in the supplemental
material). pCR3.1-Uni was provided in a linear form with overhanging Ts at each
end. The 5 overhang was also predephosphorylated, enabling the 5-phosphor-
ylated PCR fragments to ligate only in the correct orientation for expression
from an upstream cytomegalovirus promoter. Portions (5 to 10 l) of the ligation
reaction were used to transform competent TOP10F bacteria. Minipreps were
prepared from resulting colonies, and the presence of inserts was screened by
digestion using appropriate restriction enzymes. Variable V1V2 loop sequences
were obtained for all patient envelopes amplified to confirm the presence of
novel sequences and the lack of contamination with standard HIV-1 envelopes.
Molecular constructs required for pseudotype virus production. Constructs
used to prepare pseudotype viruses are shown in the supplemental material.
Figure S1 shows pseudotype viruses carrying each patient envelope that were
produced by cotransfection of env pSVIIIenv (14) with an env pNL43 molec-
ular clone into 293T cells using calcium phosphate. Pseudotype viruses prepared
using the pSVIIIenv vector for envelope expression contained infectivity that
was more than 100-fold higher than that of pCR3.1-Uni pseudotypes (data
not shown). All patient-derived envelope genes were therefore cloned into
pSVIIIenv via conserved KpnI sites for the production of pseudotype viruses.
Cell supernatants carrying progeny pseudotype virions were harvested 48 h after
transfection, clarified (1,000  g for 10 min), aliquoted, and stored at 152°C.
Preparation of PBMCs and macrophages. Fresh blood (from volunteer do-
nors) was diluted 1:1 in RPMI 1640 medium and carefully layered onto 15 ml of
Ficoll-Hypaque (Pharmacia) in a 50-ml Falcon tube and centrifuged at 350  g
for 30 min at room temperature. Erythrocytes sedimented at the bottom of the
tube, while the white cells were harvested from the interphase between Ficoll and
diluted plasma. These cells were washed twice in RPMI 1640 and resuspended to
give 1  106 cells/ml in RPMI 1640 containing 10% fetal calf serum (FCS) and
0.5 g of phytohemagglutinin/ml. The cells were then grown for 2 to 3 days. Cells
were then diluted to 3  105 to 5  105 cells/ml and cultured for a further 2 to
3 days in media supplemented with 10% FCS and human interleukin-2 (from
human lymphocytes, 20 U/ml; Boehringer) prior to infection. Macrophages were
also prepared from the Ficoll white cell layer as described previously (41).
Briefly, 108 cells were plated onto a 14-cm-diameter bacterial petri dish in 15 ml
of Dulbecco’s modified Eagle medium (DMEM) containing 10% human serum.
Cells were incubated for 2 h at 37°C. The adherent cells were then gently washed,
first with the media on the plate and then twice with fresh DMEM before 15 ml
of DMEM containing 10% human serum was added, and cells were incubated at
37°C overnight. The following day, adherent cells were washed again, and fresh
media was added. Macrophages were ready for infection 5 to 7 days later. The
day prior to infection, the macrophages were washed three times in EDTA and
incubated at 37°C for 10 min to loosen cell attachments. Macrophages were then
gently scraped off the dish by using a cell scraper. Cells were resuspended in
DMEM containing 10% human serum, counted, and reseeded into 48-well tissue
culture trays at 1.25 105 cells per well. Alternatively, elutriated monocytes (18)
were resuspended in medium containing macrophage colony stimulating factor
(R&D Systems) and cultured for 7 days before use for virus infections.
TABLE 1. Patient details
Patient no. Statusa Characteristics Sample(s)
NA118 IVDU Dementia, florid giant-cell encephalitis Frontal lobe, LN
NA420 Heterosexual No cognitive impairment, sparse giant-cell encephalitis Frontal lobe, LN
NA20 Hemophiliac Mild cognitive impairment, sparse giant-cell encephalitis, cerebral toxoplasmosis Frontal lobe
NA176 IVDU Dementia, focal giant-cell encephalitis Frontal lobe
NA353 IVDU Mild cognitive impairment, florid giant-cell encephalitis Frontal lobe
a IVDU, intravenous drug user.
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Cell lines expressing CD4 and coreceptors. Coreceptors used by pseudotype
viruses carrying patient-derived envelopes were investigated by testing infection
of the CD4 GHOST (2a) and NP2 (42a) sets of cell lines. Infectivity via CCR2b,
CCR3, CCR5, CX3CR1, CXCR6, and GPR15 was tested on GHOST cells.
Infection via CCR3, CCR5, CCR8, GPR1, APJ, and CXCR4 was tested on
NP2/CD4 cells. CD4-independent infection was assessed on NP2/CCR5 cells.
GHOST and NP2/CD4 cell lines and their derivatives were seeded into 48-well
trays on the day prior to infection; 0.5 ml of GHOST (4  104 cells/ml) or
NP2/CD4 (5  105 cells/ml) cells were seeded per well. Infections were per-
formed in duplicate and repeated at least once. One hundred microliters of
serially diluted, cell-free virus supernatant was incubated with the appropriate
cell lines for 3 h at 37°C before addition of 400 l of growth medium. Cells were
fixed and immunostained for virus antigens 3 days postinfection, and the foci of
infection per milliliter was calculated (see below).
p24 antigen immunostaining. Immunostaining was carried out as previously
described (6). HIV-infected cells were washed once in phosphate-buffered saline
(PBS) and then fixed in cold (20°C) methanol-acetone at a ratio of 1:1 for 10
min at room temperature. The cells were then washed once with PBS and once
with PBS containing 1% FCS before adding anti-HIV-1 p24 monoclonal anti-
bodies (38:96K and EF7; Centralised Facility for AIDS Reagents, Potters Bar,
United Kingdom). These monoclonal antibodies were added as hybridoma cell
culture fluid at a 1:1 ratio diluted 1 in 40 in PBS–1% FCS and incubated at room
temperature for at least an hour. Cells were washed once in PBS–1% FCS before
incubating for 1 h at room temperature with anti-mouse F(ab)2 fragments
conjugated to -galactosidase (Southern Biotechnology Associates, Inc.) at a
dilution of 1 in 400 in PBS–1% FCS to detect the first antibody layer. Cells were
then washed once with PBS–1% FCS and twice with PBS. Infected cells were
stained blue on addition of X-Gal substrate (0.5 mg of 5-bromo-4-chloro-3-
indolyl--D-galactopyranoside/ml [Fisher Bioreagents Inc.], 3 mM potassium fer-
rocyanide, 3 mM potassium ferricyanide, 1 mM magnesium chloride). The pre-
pared pseudotype viruses were competent only for single rounds of replication.
Thus, individuals or groups of recently divided blue-stained cells were regarded
as foci of infection, and virus infectivity was estimated as focus-forming units
(FFU) per milliliter. Supplemental Fig. S1D and E show immunostained NP2/
CD4/CCR5 cells and primary macrophages following challenge with an R5
envelope-positive pseudotype virus. Foci formation required both CD4 and
CCR5 and was blocked by 1 M 3-azido-3-deoxythymidine.
Cell-cell fusion assays. Cell-cell fusion was evaluated by cocultivating 293T
cells transfected with env pSVIIIenv and env pNL43 with appropriate test
cells. Thus, coreceptor-positive NP2/CD4 or GHOST cells were seeded at 4 
104 to 5 104 cells per well in 48-well culture dishes, while primary macrophages
were prepared as described above and seeded at 2.5  105 per well in 48-well
culture dishes and incubated overnight. 293T cells were transfected as described
above and also incubated overnight. Each transfected 293T cell culture was
trypsinized, and 50 l of cells (5 105 cells/ml) was cocultivated with coreceptor-
positive NP2/CD4 cells, GHOST cells, or macrophages. After 6 h of incubation,
cocultivations with coreceptor-positive NP2/CD4 or GHOST cells were washed
in PBS and fixed for 10 min in methanol containing 1% methylene blue and
0.25% basic fuchsin. Fixed cells were destained in PBS and examined by light
microscopy for the presence of syncytia. Macrophage cocultivations were ob-
served over 3 days and fixed when syncytia were apparent.
Nucleotide sequence accession numbers. GenBank accession numbers for the
V1V2 and V3 loops presented here are as follows: V1V2 loops, AY569981 to
AY569999; V3 loops, AY570000 to AY570018.
RESULTS
Sequence analysis of envelope genes amplified from patient
brain and LN tissue samples. We first sequenced the variable
V1V2 loops of each envelope clone obtained to identify indi-
vidual genotypes and to omit replicate clones from further
study. A total of 19 distinct V1V2 genotypes were identified
from the five patients (Table 2). V1V2 sequences were distinct
for each patient. NA118 and NA420 sequences are also closely
related with previously published envelope sequences from
these individuals (17). For NA420, brain and LN V1V2 se-
quences were clearly distinct genotypes consistent with tissue-
specific evolution. For NA118, brain and LN V1V2 sequences
revealed distinct genotypes; however, specific compartmental-
ization was less clear, as previously reported for this individual
(17).
V3 loop charge. The overall positive charge of the V3 loop
has been used as an important indicator of HIV-1 tropism as
either syncytium inducing or non-syncytium inducing (12). Syn-
cytium-inducing and non-syncytium-inducing phenotypes are
now known to represent viruses that use CXCR4 or are pre-
dominantly CCR5 using, respectively (2). All V3 loop se-
TABLE 2. V1V2 loop amino acid sequences of patient envelopes
Patient Source Clone V1V2 sequencea
NA118 LN LN9 CTDARNTTTN....TTGD.....SWKRMEKGELKNCSFNITTSMRDKMQKEYALFYKLDVVPIDDN.SSNNTSNYSSYRLISC
LN27 ––––T–––GGSGGN––G.NTTSG–––M––––––––––––––––I–––––––––––––––––S––K–N.–G...––––––––––
LN33 ––––––––R–...N––DG.....––QK––Q––––––––––––––––––––––––––––––––––––.––––––––––––––––
Brain B12 CTDATNNTSGSSKNTTG.NTTSGSWKMMEKGELKNCSFNITTSIRDKMQKEYALFYKLDVVQIDNNNSSHDNSNYSSYRLVSC
B18 –––WN–TATSDR––D–..––––AG––––––––I––––––––––––––––––––––––––––P––D–S–.NNT––––D–––I––
B44 ––––––T–G––GG––––.–––––––––––––––––––––––––––––––––––––––––––P–––D–––.––...–––––I––
B45 ––––––T–G––GG–––SD––––––––I–––––I–––––––––––K–––––––––––––––––––KD–––K–.––––––––I––
NA420 LN LN40 CTDLRNATNTNSSSERK.MEEGEIKNCSFYVTPTLRDKKQKEYATFYKLDVMPIDKDNTSYRLISC
LN85 ––––––––––––––GRIM–EG––––––––––S–N–––R––––––––––––––––––––––––––––
Brain B3 CTDLKNATNTNSSSGR.MMEGGAIKNCSFNI..SIRGKVQKEYAFFYKLDVIPIENDTTSYRLISC
B13 ––––R–––––––––––.––––––––––––––..–––––––––––––––––––––––––––––––––
B33 –––FR–––––––––––.–––––E––––––––..–––D–––––––––––––––––––––––––––––
B42 –––F––––––––––––.V––––E––––––––..–––––––––––––––––––––––––––––––––
NA20 Brain B59 CTDWRKNATAITTATPSSSEGTLEGGEMKNCSFNITTSIRDKVKKEYALFYRLDVVPIENDNTSYRLISC
B76 ––––––––––T–––––––RG––––––––––––––––––––––––––––––––––––––––––––––––N–
NA176 Brain B72 CTDWKSNANTTNTTSSTNTTNSSGETMEGGDMKNCSFNITSNIRDKMQKEYALFYKLDVVPIGNSNTSYRIINC
B93 –––––––––I–––––––––––––––I––––––––––––––––––––––––––––––––––––––––––––––––
NA353 Brain B13 CTNANVTS––––––NTTSNSWETMEKGEIKNCSFNITTNIGGKMQKEYALFYKLDVIPIDNDTISYRLINC
B27 ––D––A––SSGNTT––––––––––––––––––––––––––S––––––––––––––––––––––––––––––
a Dashes indicate homology, dots indicate spaces added to maintain alignment.
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quences carried an overall charge of 3 or 4, consistent with a
CCR5-using phenotype (Table 3).
Infectivity and coreceptor use of pseudotype viruses carry-
ing LN- and brain-derived envelopes. Pseudotype viruses were
prepared by cotransfecting 293T cells with env pSVIIIenv
together with env pNL43. Pseudotype viruses were harvested
after 48 h, and their infectivity was analyzed for the GHOST
and NP2/CD4 series of coreceptor-expressing cell lines. Infectiv-
ity data for envelope-positive pseudotype viruses are shown in
Table 4. Thirteen of the 19 distinct envelope genotypes yielded
pseudotypes with infectivity for both GHOST/CCR5 and NP2/
CD4/CCR5 cells. Infectivity of these pseudotypes was compa-
TABLE 3. V3 loop amino acid sequences of patient envelopes
Sample Clone V3 loop sequenceb Charge
Consensusa CTRPNNNTRKSIHIGPGRAFY
T
ATGEIIGDIRQAHC 3
NA118 LN9 CTRPNNNTRKSIHIGPGRAFYATGDIIGDIRQAHC 3
LN27 ––––––––––––––––––––––––––––––––––– 3
LN33 ––––––––––––––––––––––––––––––––––– 3
B12 CTRPNNNTRKSIHIGPGRAFYATGDIIGDIRQAHC 3
B18 ––––––––––––––––––––––––––––––––––– 3
B44 ––––––––––––––––––––––––––––––––––– 3
B45 ––––––––––––P–––––––––––E–––––––––– 3
NA420 LN40 CTRPNNNTRKSIHLGPGRAFYTTGEITGDIRQAHC 3
LN85 ––––––––––––––––––––––––––––––––––– 3
B3 CTRPNNNTRKSINLGPGRALYTTGEITGDIRQAHC 3
B13 –––––––––––––––––––F––––––I–––––––– 3
B33 ––––––––––––––––––––––––––––––––––– 3
B42 ––––––––––––––––––––––––––I–––––––– 3
NA20 B59 CTRPNNNTRKSIHLGPGSAFYTTGQILGDIRQAHC 3
B76 –––––––––––––M–––RV––A––A–T–––––––– 4
NA176 B72 CTRPNNNTRKGIHIGPGRAFYTTGEIIGNIRQAHC 4
B93 ––––––––––––––––––––––––––––––––––– 4
NA353 B13 CTRPNNNTRKGIHIGPGRAFYATGEIIGDIRQAHC 3
B27 ––––––––––––––––––––––––––––––––––– 3
a Consensus V3 sequence for R5 envelopes (4).
b Dashes indicate homology.
TABLE 4. Summary of macrophage syncytia induction by patient and control envelopes
Patient Envelopea
Infectivity (FFU/ml) for:
NP2/CD4 GHOST
CCR3 CCR5 CCR8 CXCR4 GPR1 APJ CCR2b CCR5 GPR15 CXCR6 CX3CR1
NA118 LN27 41,000 8,900 —b — — — — 23,500 — — —
LN33 6,650 24,000 — — — — — 12,200 — — —
B12 32,100 40,100 — — — — — 179,000 — — —
B45 — 210 — — — — — 565 — — —
NA420 LN40 120 1,105 — — — — — 590 — — —
LN85 20 120 — — — — — 510 — — —
B13 230 37,850 — — — — — 44,000 — — —
B33 — 72,500 — — — — — 68,000 — — —
B42 — 12,400 — — — — — 14,500 — — —
NA20 B59 40,500 56,500 3,750 — 420 — — 38,000 710 215 —
B76c 6,000 16,300 — — — — — 15,650 — — —
NA176 B72 139 7,650 — — — — — 8,100 — — —
B93 13,480 43,600 — — — — — 32,000 — — —
NA353 B27 19,100 114,500 — — — — — 187,000 — — —
a Only results for functional envelopes are shown. Other envelopes (NA118 LN09, NA118 B18, NA118 B44, NA420 B03, and NA353 B13) failed to confer infection
of the coreceptor-positive cells shown.
b —, 10 FFU/ml.
c Repaired envelope (see text on the next page).
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rable to pseudotypes carrying well-characterized HIV-1 enve-
lopes, e.g., SF162. Some envelopes (NA20 B76, NA353 B13,
NA118 B18, NA118 B44, NA118 LN9, and NA420 B3) failed
to yield infectious pseudotype viruses, while others consistently
yielded pseudotypes with lower levels of infectivity (NA118
B45, NA176 B72, NA420 LN85, and NA420 LN40). Three
distinct phenotypes of coreceptor use were observed. First,
some envelopes, e.g., NA420 brain envelopes B33, B42, and
B13, were mainly restricted for CCR5 use and unable to infect
cells expressing other coreceptors. Second, the majority of
functional envelopes consistently used CCR3 in addition to
CCR5 but did not use other coreceptors. Third, a single enve-
lope genotype from NA20 (B59) showed a broader use of
coreceptors, including CCR3, CCR8, GPR1, GPR15, CXCR6,
and CCR5 (Table 4).
Cell-cell fusion induced by patient envelopes. The capacity
of the different patient-derived envelopes to induce cell-cell
fusion was evaluated. 293T cells were cotransfected with the
pNL43 env plasmid together with each patient env pSVII-
Ienv construct. After overnight incubation, the transfected
293T cells were trypsinized and cocultivated with different
CD4, coreceptor-positive cell lines (the GHOST and NP2/
CD4 series of coreceptor-expressing cell lines). After incuba-
tions between 4 h and overnight, cocultivations were fixed and
stained as described in Materials and Methods. Typical spread-
ing syncytia were observed in cocultivations (Fig. 1). Syncytium
induction assays confirmed the coreceptor use detected by
infectivity assays described above. For example, envelopes that
conferred infection of NP2/CD4/CCR3 also induced cell-cell
fusion with this cell line (data not shown). The broad corecep-
tor use by NA20 envelope B59 was also confirmed by induction
of syncytia via CCR5, CCR3, CCR8, GPR1, and very weakly
via CXCR4 (but not via APJ) on NP2/CD4 cells and via
GPR15 and CXCR6 on GHOST cells (Fig. 1). Cell-cell fusion
was not detected for any other patient envelope via CXCR4
expressed either on NP2/CD4 or on GHOST cells. However,
these CXCR4 cells supported extensive syncytium formation
when cocultivated with 293T cells expressing the X4 envelope
of NL43 (data not shown).
Patient envelopes that failed to yield infectious pseudotypes
also failed to induce cell-cell fusion. This result suggests that
these envelopes carry a defect(s) that eliminates their capacity
to function in these assays, as reported for other envelopes
PCR amplified from patient tissue (28). This conclusion is
supported by the NA20 B76 envelope, where a single prema-
ture stop codon, identified in the extracellular domain of gp41
(data not shown), precluded the production of a full-length
functional envelope. Repair of this stop codon restored full
function to the NA20 B76 envelope. The repaired NA20 B76
was shown to be an R3R5 envelope similar to the majority of
patient envelopes described here but distinct from the broadly
tropic B59 envelope also from NA20 (Table 4).
Two patient envelopes, NA420 LN40 and NA420 LN85,
consistently yielded pseudotypes that carried only low-level
infectivity for GHOST/CCR5 and NP2/CD4/CCR5 cells. In-
terestingly, these envelopes were fully functional for cell-cell
fusion and induced syncytia formation on both GHOST/CCR5
and NP2/CD4/CCR5 cells. Moreover, both low-infectivity en-
velopes conferred cell-cell fusion in NP2/CD4/CCR3 cells,
confirming an R5R3 phenotype. Both NA420 LN40 and
NA420 LN85 envelopes contained mutations in the gp41 cy-
toplasmic domain, mutations that severely reduced their incor-
poration onto budding virions (data not shown). These enve-
lopes were also restored to full infectivity by preparing
FIG. 1. Coreceptor use of NA20 B59 envelope evaluated by cell-cell fusion assays. NA20 B59-induced syncytia in GHOST and NP2/CD4 cells
expressing a range of different coreceptors but not in the parental cell lines lacking coreceptors.
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chimeric constructs that contained gp120 sequences from ei-
ther NA420 LN40 or NA420 LN85 and gp41 sequence from
NA420 B33.
Infection and cell-cell fusion of primary macrophage cul-
tures. Both Gorry’s UK1-br brain isolate (16) and Shieh’s
microglia-passaged BORI variant (39) were reported to be
more infectious and fusigenic for microglial cells and macro-
phages. We therefore compared the capacity of the patient-
derived envelopes to confer infectivity and syncytium induction
in primary macrophage cultures. Patient env pseudotypes
with high infectivity titers on CD4 CCR5 cell lines also
infected primary macrophages (Fig. 2A). Ratios of patient
env pseudotype infectivity for macrophages compared to
those for GHOST/CCR5 are shown in Fig. 2B. These results
indicate that four brain envelopes infected primary macro-
phages efficiently, while other patient envelopes conferred less-
efficient or no infection. We also tested envelopes of several
well-characterized HIV-1 strains including macrophage-tropic
(SF162 and AD8) and brain- or cerebrospinal fluid-derived
(YU2, JRFL, and JRCSF) viruses. These envelopes were
cloned from infectious molecular clones into pSVIIIenv. Four
of these (YU2, JRFL, SF162, and AD8) conferred infection of
primary macrophage cultures. However, at least two of the
brain-derived patient envelopes (NA20 B59 and NA353 B27)
conferred even higher macrophage-GHOST/CCR5 infectivity
ratios, indicating that these envelopes carry an enhanced mac-
rophage tropism. Both R5 and R5R3 patient envelopes segre-
gated with macrophage-tropic and non-macrophage-tropic en-
FIG. 2. Infection of primary macrophages by patient LN and brain envelopes. (A) Infectivity titers for patient envelope-positive pseudotype
viruses titrated on primary macrophages from different donors and on GHOST/CCR5 cells. Arrows indicate that infection is below the level of
detection. Data are derived from duplicate infections on two donor macrophage batches. GHOST/CCR5 titers were derived from infectivity
titrations carried out with the same batch of virus as in macrophage infections. (B) Macrophage-GHOST/CCR5 infectivity ratios indicate that
patient envelopes NA20 B59, NA353 B27, NA420 B33, and NA176 B93 are highly macrophage tropic.
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velopes, and thus no obvious association was observed between
CCR3 use and macrophage infection.
NA118 B12, LN27, and LN33 envelopes failed to confer
macrophage infection, even though they conferred high infec-
tivity for GHOST/CCR5. The three NA420 brain envelopes
conferred macrophage infection with NA420 B33 infecting
most efficiently of the three. In contrast, both repaired NA420
LN envelopes failed to confer any macrophage infection.
Taken together, these results show that all LN-derived enve-
lopes were non-macrophage tropic, while most brain-derived
envelopes (all except NA118 B12) conferred macrophage in-
fection (Fig. 2A and B).
We next evaluated the capacity of patient envelopes to in-
duce cell-cell fusion in primary macrophage cultures. These
fusion assays were carried out by cocultivation of primary mac-
rophage cultures with 293T cells cotransfected with patient
env pSVIIIenv and env pNL43 vectors as described in Ma-
terials and Methods. A minority of envelopes induced very
large and spreading macrophage syncytia containing numerous
nuclei (Fig. 3). The same four patient envelopes that efficiently
infected macrophages consistently induced large spreading
syncytia over 2 to 3 days of coculture. The extent of macro-
phage syncytia induction was donor dependent. Of the well-
characterized control envelopes (YU2, JRCSF, JRFL, SF162,
and AD8), only AD8 conferred levels of macrophage syncytia
similar to the patient brain envelopes described above. Mac-
rophage syncytium induction is summarized in Table 5.
Brain-derived HIV-1 envelopes are not CD4 independent.
Several studies have correlated SIV macrophage tropism with
the capacity to infect CCR5 cell lines in vitro in the absence
of CD4 (24, 31). We therefore tested whether pseudotype
viruses carrying patient envelopes could infect CD4 NP2/
CCR5 cells. We also tested a primary HIV-2 strain (ALI) that
was previously shown to infect CCR5 cells in the absence of
CD4 (33). In contrast to HIV-2 ALI, none of the brain or LN
envelopes conferred any infection of CD4 NP2/CCR5 cells
(data not shown), even though many envelopes conferred high
levels of infection on NP2/CD4/CCR5 cells (Table 4). It was
previously shown that pretreatment of HIV-2 with soluble
CD4 induced infection of CD4 cells (6). However, soluble
CD4 (1 g/ml) had no effect on the capacity of patient enve-
lopes to confer infection or cell-cell fusion of CD4 NP2/
CCR5 cells (data not shown). Together, these observations
show that all the patient envelopes investigated here, whether
from LN or brain, were completely dependent on cell surface
CD4 for infection and cell-cell fusion.
Some brain envelopes can infect cells expressing low levels
of CD4 and/or CCR5. Although, none of the patient envelopes
studied here were CD4 independent, it was possible that brain
envelopes required less cell surface CD4 to trigger infection as
described by Gorry et al. (16) and Martin et al. (23). We
therefore tested the capacity of pseudotype viruses carrying
brain and LN envelopes to infect HeLa cells expressing either
high or low levels of CD4 and three different levels of CCR5
(30). Platt et al. reported that the high CD4 clones express
approximately 4  105 molecules/cell and the low CD4 clones
express approximately 104 receptors/cell. Low, medium, and
high CCR5 clones were reported to express approximately 2 
103, 104, and 105 molecules/cell, respectively. Immunostaining
FIG. 3. Syncytium induction in primary macrophages by patient
brain-derived envelopes. Large spreading syncytia induced by patient
brain envelopes NA176 B93 and NA353 B27 are shown. Note that the
syncytia shown contain hundreds of nuclei (top panels). No syncytia
were induced by NA176 B72 or the nonfunctional NA353 B13 (bottom
panels).
TABLE 5. Summary of macrophage syncytia induction by patient
and control envelopes
Patient envelopes Phenotypea Cell-cell fusion inmacrophagesb
NA118 LN27 R5R3 
NA118 LN33 R5R3 
NA118 B12 R5R3 
NA420 LN40 R5R3 
NA420 LN85 R5R3 
NA420 B13 R5 
NA420 B33 R5 
NA420 B42 R5 
NA20 B59 R5R3 
NA20 B76 R5R3 
NA176 B72 R5R3 
NA176 B93 R5R3 
NA353 B27 R5R3 
SF162 R5 
JRCSF R5 
JRFL R5R3 
AD8 R5R3 
YU2 R5R3 
a Coreceptor use of control envelopes (SF162, JRCSF, JRFL, AD8, and YU2)
was taken from the HIV sequence database (http://www.hiv.lanl.gov/). , use of
additional coreceptors; , use of several additional coreceptors.
b Cell-cell fusion data are representative of at least three independent exper-
iments. Cell-cell fusion in GHOST/CCR5 cells and primary macrophages was
assessed by the extent of syncytium formation following overnight cocultivation
with 293T cells transfected with env pSVIIIenv and env mutant pNL43. For
GHOST/CCR5 cells, all envelopes showed extensive syncytium formation involv-
ing over 50% of plated cells. Syncytium formation for primary macrophages is
represented as follows: , no syncytia formed; , 0 to 10 large syncytia observed
per well of a 48-well culture dish; , 10 to 25 syncytia per well; , 25
syncytia per well.
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and fluorescence-activated cell sorter analysis confirmed that
these different clones expressed low or high CD4 and low,
medium, or high CCR5 amounts on their cell surfaces.
All envelopes tested were capable of infecting HeLa cells
expressing high levels of CD4 and different levels of CCR5
(Fig. 4). Infection of HeLa/HiCD4 cells with the lowest CCR5
was within 1 log of maximum infectivity recorded in the pres-
ence of the highest CCR5 levels. In contrast, infectivity re-
corded on HeLa cells with low levels of CD4 (HeLa/LowCD4)
showed that only particular envelopes were able to infect these
cells efficiently (Fig. 4). These included the four brain-derived
envelopes that scored highest for macrophage fusion and in-
fection. Infection by patient NA118 envelopes (B12, LN27, and
LN33) was severely affected by CD4 expression. NA420 brain
and LN envelopes clearly segregated into separate phenotypes
with NA420 B33, B13, and B42 envelopes conferring infection
of HeLa/LowCD4 relatively efficiently, while infection by the
repaired NA420 LN envelopes was below the level of detection
on cells expressing low levels of CD4. JRCSF showed a CD4
requirement similar to those of the NA118 and NA420 LN
envelopes. Several of the control macrophage-tropic HIV-1 en-
velopes (AD8 as well as brain tissue-derived YU2 and JRFL)
also infected in the presence of low CD4 and low CCR5. These
envelopes were as efficient on the HeLa/LowCD4/CCR5 cul-
tures as were patient brain envelopes NA20 B59 and NA353
B27.
Dejucq et al. previously reported that particular R5 HIV-1
isolates were able to infect the CD4 T-cell line MOLT 4.
Although these cells express high levels of CD4, CCR5 expres-
sion was undetectable by flow cytometry and only weakly de-
tectable by reverse transcription-PCR (7). Nevertheless,
MOLT 4 infection by R5 isolates was completely inhibited by
CCR5-specific ligands (7). Here, we tested whether the patient
envelopes could infect or induce cell-cell fusion of MOLT 4
cells. The four macrophage-tropic brain-derived envelopes
conferred infection of MOLT 4 cells (data not shown) and
were able to induce the formation of large syncytia (Fig. 5).
Syncytium formation by NA20 B59 and by NA176 B93 was
completely blocked by TAK779 and unaffected by a range of
ligands for other potential coreceptors, including AMD3100,
the ligand for CXCR4 (data not shown). Several other patient
envelopes induced low levels of small syncytia. Of the control
envelopes, only AD8 and YU2 consistently induced low levels
of MOLT 4 syncytia.
Together these results show that four brain-derived enve-
lopes were capable of exploiting low levels of CD4 and/or
CCR5 for infection and cell-cell fusion of macrophages and T
cells.
Sensitivity of patient envelopes to inhibition by ligands to
CD4 and CCR5. We next tested whether the distinct pheno-
types of the patient envelopes impacted on their sensitivity to
inhibition by reagents that blocked either CD4 or CCR5. We
first tested the blockade of CCR5 by TAK779. GHOST/CCR5
cells were treated with twofold dilutions of TAK779 for 1 h
before challenging with 100 to 200 FFU of patient envelope-
positive pseudotype viruses as described in Materials and
Methods. Inhibition was assessed as 90% inhibitory concentra-
tions (IC90s) (Fig. 6). A range of IC90s was evident and no clear
association of TAK779 sensitivity and envelope phenotype
could be seen (Fig. 6A). IC90s were also obtained for envelope-
FIG. 4. Infection of cells expressing low levels of CD4 and/or CCR5 by patient envelopes. Infection of HeLa/HiCD4 cells expressing high levels
of CD4 and three different amounts of CCR5 (top panels). Infection of HeLa/LowCD4 expressing low levels of CD4 and three different amounts
of CCR5 (bottom panels). Infectivity was assessed as FFU per milliliter by immunostaining for p24 as described in Materials and Methods. Values
plotted are the average FFU counts for duplicate wells in a single experiment. Similar data were obtained from at least one repeat experiment.
Results for different envelopes are grouped into separate graphs to avoid congestion.
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positive pseudotype inhibition by Q4120 (Fig. 6B). Q4120 is a
monoclonal antibody that recognizes the N-terminal domain of
CD4 and blocks gp120 binding and infectivity. In contrast to
TAK779, Q4120 IC90s showed a strong correlation with patient
envelope phenotype. The four brain-derived envelopes that
showed enhanced fusigenicity and tropism for macrophages
and MOLT 4 cells required the highest doses of Q4120 for
inhibition. These results are consistent with an increase in
envelope affinity for CD4, conferring an adaptation to infect
cells expressing low levels of CD4. Of note, all four LN enve-
lopes clustered along with JRCSF as the most sensitive to
Q4120 inhibition. These results are consistent with the hypoth-
esis that envelopes that evolve a higher affinity for CD4 will
have an increased tropism for cells expressing low levels of
CD4 and/or CCR5, including both macrophages and T cells.
DISCUSSION
We have characterized the biological properties of complete
envelope genes amplified by PCR from brain tissue of five
AIDS patients with neurological conditions. For two of the
patients, envelope genes were also successfully recovered from
LN tissue. We have identified highly macrophage-tropic and
fusigenic envelopes in brain tissue of four of the five patients.
Two very distinct envelope phenotypes were observed. A group
of four brain envelopes were highly macrophage tropic and
infected cells expressing low amounts of CD4 or CCR5. The
LN envelopes formed a second group that failed to confer mac-
rophage infection and required substantially higher amounts of
CD4 for infection.
The potential impact of PCR error on envelope phenotype.
Investigation of HIV-1 cell tropism has generally been carried
out using viruses isolated into PBMCs. This approach is likely
to be a highly selective process that will amplify virus strains
that replicate fastest in CD4 T cells and may overlook virus
strains adapted for replication in specialized cells resident in
particular tissues or organs. This possibility is potentially im-
portant for HIV in the brain, where perivascular macrophages
and microglial cells that express low levels of CD4 (1, 21, 26)
are the predominant infected cell types. In this study, we have
used PCR techniques to amplify HIV-1 envelope sequences
directly from brain tissue samples, thus avoiding possible se-
lection in culture. PCR amplification of viral sequences also
has limitations and may result in the introduction of mutations
into the DNA products. The proofreading enzymes used here
help to minimize this possibility, and the majority of PCR-
amplified envelopes described here were fully functional.
We were still concerned that envelopes carrying PCR-intro-
duced errors may appear functional yet carry less-obvious de-
fects. For example, NA118 and NA420 LN envelopes all failed
to confer macrophage infection, were most sensitive to Q4120
inhibition, and required high levels of CD4 for infection. The
reduced efficiency of these envelopes could potentially be due
to PCR-introduced errors that affect the capacity of an enve-
lope to mediate infection. Thus, PCR-introduced sequence
errors would be expected to render such envelopes generally
more sensitive to all inhibitors of infection. However, these
envelopes were not sensitive to all inhibitors and varied con-
siderably in their sensitivity to TAK779 inhibition with the
NA118 LN33 envelope, the most resistant (Fig. 6). Alterna-
tively, PCR-introduced errors may impact on the amount of
envelope processed into gp120 and gp41 and assembled onto
virions. The patient envelopes showed some variation in the
amount of envelope processed and on virions, but this did not
correlate with other envelope properties reported here. For
instance, NA118 envelopes were processed and incorporated
into virions as efficiently as the most macrophage-tropic enve-
lope, NA353 B27 (data not shown). Finally, the JRCSF enve-
lope was cloned from an early PBMC culture of isolated virus
(20) and was not derived by PCR, yet it showed a similar
requirement for high CD4 for infection and failed to confer
macrophage infection. Our results show a wide variation in
envelope requirement for CD4 to induce infection that is not
related to PCR amplification procedures. We therefore believe
that these procedures are a viable alternative to virus isolation
for the study of HIV envelope phenotype.
Compartmentalized envelope evolution and sampling is-
sues. Study subjects NA118 and NA420 were previously re-
ported to carry distinct V3 loop envelope sequences in brain
and LN consistent with compartmentalized evolution (9).
V1V2 and V3 sequences of the NA420 envelopes studied here
were also distinct for brain versus LN origins (Tables 2 and 3).
Phenotype analyses showed that these sequence differences
FIG. 5. Cell-to-cell fusion induced by patient envelopes in MOLT
4 cells that express very low levels of CCR5. 293T cells expressing
different patient envelopes were cocultivated with MOLT 4 cells. The
presence of syncytia was assessed by light microscopy after overnight
incubation. Arrows mark examples of syncytia. The control panel
shows cocultivation of MOLT 4 with 293T cells transfected with a
pSVIIIenv carrying a defective envelope.
VOL. 78, 2004 ANALYSIS OF HIV-1 R5 ENVELOPES BY PCR FROM BRAIN TISSUE 6923
translated into biological differences. Specifically, the three
brain envelopes were specific for infection via CCR5 and could
confer infection of cells expressing low levels of CD4, including
macrophages. In contrast, NA420 LN envelopes were able to
fuse with cells expressing either CCR3 or CCR5 but required
high levels of CD4 for infection and failed to confer infection
of macrophages. These observations are consistent with com-
partmentalized phenotype evolution occurring in parallel with
genotype evolution. All envelopes described here were ampli-
fied from brain or LN tissue samples. Since tissues contain a
mixture of cell types and brain tissue also contains blood cap-
illaries and blood cells, it is not possible to know definitively
their cellular origin.
Coreceptor use. There was no correlation between corecep-
tor use and tissue of origin for the envelopes investigated.
Moreover, no correlation was apparent between coreceptor
use and other envelope properties, e.g., macrophage infectiv-
ity. Only the NA420 brain envelopes were restricted to infec-
tion via CCR5. All other functional envelopes conferred infec-
tion of CD4 NP2 cells via CCR3 and CCR5. Intriguingly,
infectivity titers recorded on NP2/CD4/CCR3 were nearly as
high as those for NP2/CD4/CCR5 cells (Table 4). The signif-
icance of CCR3 use by the majority of envelopes amplified is
unclear, since there is no current evidence to indicate that
CCR3 is used in vivo or is more than a minor coreceptor.
NA20 B59 carries a V3 loop that has a low overall charge,
consistent with an R5 phenotype. This envelope used a broad
range of different coreceptors, including CXCR4, albeit
weakly. Ohagen’s study (28) also detected several low-V3-
charged envelopes that conferred broad coreceptor use. This
type of envelope may therefore represent a new category of
HIV-1 envelope that needs to be considered in the light of new
therapies that target CCR5.
Brain envelopes and macrophage tropism. We identified
envelopes that were highly fusigenic and tropic for primary
macrophages in brain tissue from four of the five patients.
These envelopes were also able to confer infection of cells
expressing low levels of CD4 and CCR5. It was possible that
these envelopes represented a distinct category for CCR5-
using viruses. Alternatively, they might simply be macrophage
tropic, a phenotype expected for envelopes from the brain,
where the main cell types infected are of monocyte/macro-
phage lineage. We therefore included in our study several
well-characterized macrophage-tropic HIV-1 envelopes to
help evaluate whether the enhanced fusigenicity and macro-
phage tropism of the four patient envelopes was a distinct
outlying phenotype. Our results show that the four brain en-
velopes are at the upper limit of a range of macrophage fusi-
genicity and tropism. Of the five control envelopes, the AD8
envelope was the most fusigenic for primary macrophages and
showed a capacity for infection of cells with low levels of CD4
similar to those of the four highly macrophage-tropic, brain-
derived envelopes.
Broadening of tropism for both macrophages and T cells.
The heightened macrophage fusigenicity and tropism corre-
lated with increased resistance to inhibition by Q4120, an an-
tibody that binds domain 1 of CD4 and blocks infection. How-
ever, sensitivity to inhibition by TAK779 was apparently not
closely associated with macrophage tropism. These results are
consistent with an increased affinity of the brain envelopes for
CD4 that confers the capacity to infect cells expressing low
levels of CD4. As reported by others (16, 23, 39), this adapta-
tion may confer more-efficient replication in brain microglia
and macrophages, which express relatively low levels of CD4.
Whether the four brain envelopes have evolved in response to
selective pressures in the brain or whether envelopes with
FIG. 6. Sensitivity of patient envelopes to CCR5 and CD4 ligands. (A) TAK779 (CCR5 inhibitor) IC090 0 inhibitory doses. (B) Q4120
(anti-CD4 domain 1) IC090 0 inhibitory doses. Black symbols represent macrophage-tropic patient envelopes. Gray symbols are other patient
envelopes. Striped symbols are control, well-characterized HIV-1 envelopes. Data shown are derived from a single experiment and are represen-
tative of data from several experiments.
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similar properties are present in other tissues (17, 48) is un-
clear from the present study. Indeed, the most macrophage-
tropic envelopes were also able to infect and fuse with the
T-cell line, MOLT 4, that expresses very low levels of CCR5
(7). These results indicate that such envelopes are broadly
tropic for both macrophage and T-cell populations.
In summary, we have amplified complete HIV-1 envelope
genes from brain tissue of AIDS patients with neurological
conditions. Envelopes that were highly fusigenic and tropic for
macrophages were obtained from four of the five patients.
These envelopes also conferred infection and fusion of cells
expressing low levels of CD4 and/or CCR5. As suggested by
others (16, 23), we believe these envelopes are neurotropic and
adapted for replication in brain macrophages and microglial
cells that express low levels of CD4 (8, 21, 47).
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